Clinical evidence for synergy between immunotherapy and radiotherapy ( SITAR )

Suki Gill; Anna K Nowak; Samantha Bowyer; Raelene Endersby; Martin A Ebert; Alistair Cook

doi:10.1111/1754-9485.13441

Clinical evidence for synergy between immunotherapy and radiotherapy ( SITAR )

Suki Gill, Anna K Nowak, Samantha Bowyer, Raelene Endersby, Martin A Ebert, Alistair Cook

Research output: Contribution to journal › Review article › peer-review

10 Citations (Web of Science)

Abstract

Previous preclinical and clinical trials have shown promising antitumour activity and toxicity profile when employing the ‘Synergy between Immunotherapy and Radiotherapy’ (SITAR) strategy. Approximately, one in seven radiation therapy studies currently recruiting is investigating SITAR. This article reviews the range of cancers known to respond to immunotherapy and publications analysing SITAR. It sets the background for work that needs to be done in future clinical trials. It also reviews the potential toxicities of immunotherapy and discusses areas where caution is required when combining treatments.

Original language	English
Pages (from-to)	881-895
Number of pages	15
Journal	Journal of Medical Imaging and Radiation Oncology
Volume	66
Issue number	6
Early online date	14 Jun 2022
DOIs	https://doi.org/10.1111/1754-9485.13441
Publication status	Published - Sept 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/1754-9485.13441Licence: CC BY-NC-ND

Cite this

@article{257c6201c4ac4ab5a14b8958a3092f9f,

title = "Clinical evidence for synergy between immunotherapy and radiotherapy ( SITAR )",

abstract = "Previous preclinical and clinical trials have shown promising antitumour activity and toxicity profile when employing the {\textquoteleft}Synergy between Immunotherapy and Radiotherapy{\textquoteright} (SITAR) strategy. Approximately, one in seven radiation therapy studies currently recruiting is investigating SITAR. This article reviews the range of cancers known to respond to immunotherapy and publications analysing SITAR. It sets the background for work that needs to be done in future clinical trials. It also reviews the potential toxicities of immunotherapy and discusses areas where caution is required when combining treatments.",

author = "Suki Gill and Nowak, {Anna K} and Samantha Bowyer and Raelene Endersby and Ebert, {Martin A} and Alistair Cook",

year = "2022",

month = sep,

doi = "10.1111/1754-9485.13441",

language = "English",

volume = "66",

pages = "881--895",

journal = "Journal of Medical Imaging and Radiation Oncology",

issn = "1754-9477",

publisher = "John Wiley & Sons",

number = "6",

}

TY - JOUR

T1 - Clinical evidence for synergy between immunotherapy and radiotherapy ( SITAR )

AU - Gill, Suki

AU - Nowak, Anna K

AU - Bowyer, Samantha

AU - Endersby, Raelene

AU - Ebert, Martin A

AU - Cook, Alistair

PY - 2022/9

Y1 - 2022/9

N2 - Previous preclinical and clinical trials have shown promising antitumour activity and toxicity profile when employing the ‘Synergy between Immunotherapy and Radiotherapy’ (SITAR) strategy. Approximately, one in seven radiation therapy studies currently recruiting is investigating SITAR. This article reviews the range of cancers known to respond to immunotherapy and publications analysing SITAR. It sets the background for work that needs to be done in future clinical trials. It also reviews the potential toxicities of immunotherapy and discusses areas where caution is required when combining treatments.

AB - Previous preclinical and clinical trials have shown promising antitumour activity and toxicity profile when employing the ‘Synergy between Immunotherapy and Radiotherapy’ (SITAR) strategy. Approximately, one in seven radiation therapy studies currently recruiting is investigating SITAR. This article reviews the range of cancers known to respond to immunotherapy and publications analysing SITAR. It sets the background for work that needs to be done in future clinical trials. It also reviews the potential toxicities of immunotherapy and discusses areas where caution is required when combining treatments.

UR - http://www.scopus.com/inward/record.url?scp=85131936302&partnerID=8YFLogxK

U2 - 10.1111/1754-9485.13441

DO - 10.1111/1754-9485.13441

M3 - Review article

C2 - 35699321

SN - 1754-9477

VL - 66

SP - 881

EP - 895

JO - Journal of Medical Imaging and Radiation Oncology

JF - Journal of Medical Imaging and Radiation Oncology

IS - 6

ER -

Clinical evidence for synergy between immunotherapy and radiotherapy ( SITAR )

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this